Imcyse Awarded Subsidy from the Walloon Region for Neuromyelitis Optica Spectrum Disorder Study

  • Subsidy for €1.1 million over a period of 29 months to support the development of a therapeutic vaccination treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Funds will be used to demonstrate PoC, establish the clinical relevance of the NMOSD ImotopeTM approach and lead to a Phase I clinical trial 
  • NMOSD is a rare and severe autoimmune disease of the central nervous system dominated by inflammation of the optic nerve and spinal cord with an estimated incidence between 1-2 per 100,000

Imcyse Joins Type 1 Diabetes IMI Consortium INNODIA

Imcyse joins network of academic researchers, industry representatives and patients in collaboration to fight T1D

Consortium of 40 partners under the framework of the Innovative Medicines Initiative (IMI) offers Imcyse greater access to T1D patient populations, a platform for scientific knowledge exchange and technical approaches to further decipher its MoA.

Imcyse to present late-breaking abstract of its Imotope-based antigen-specific immunotherapy for autoimmune diseases at ASIT 2020

Oral presentation during the session Tolerance Delivery Systems & Trial Design Optimization showcases the value the Company’s novel approach to specifically target immune cells involved in autoimmune diseases 

Imcyse’s insulin-based IMOTOPETM has shown promising results in a Phase Ib study in patients with Type-1 diabetes 

With an initial focus on autoimmune diseases, Imcyse’s platform has the potential to address a wide range of indications in the vast field of immunology.